Home  |  Contact

UniProtKB/Swiss-Prot O43502: Variant p.Thr287Ala

DNA repair protein RAD51 homolog 3
Gene: RAD51C
Variant information

Variant position:  287
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Threonine (T) to Alanine (A) at position 287 (T287A, p.Thr287Ala).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and polar (T) to small size and hydrophobic (A)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  0
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In BROVCA3.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  287
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  376
The length of the canonical sequence.

Location on the sequence:   QQMISLANNHRLAVILTNQM  T TKIDRNQALLVPALGESWGH
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QQMISLANNHRLAVILTNQMTTKIDRNQ--ALLVPALGESWGH

Mouse                         QQMISLANNHRLAVILTNQMTTKIDKNQ--ALLVPALGESW

Slime mold                    QNLMNIATRYNLAVVVMNQVTTKISPNQKESILVPYLGESW

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 376 DNA repair protein RAD51 homolog 3
Alternative sequence 136 – 376 Missing. In isoform 2.


Literature citations

Submission
NIEHS SNPs program;
Cited for: NUCLEOTIDE SEQUENCE [GENOMIC DNA]; VARIANTS THR-144; CYS-249 AND ALA-287;

Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.
Meindl A.; Hellebrand H.; Wiek C.; Erven V.; Wappenschmidt B.; Niederacher D.; Freund M.; Lichtner P.; Hartmann L.; Schaal H.; Ramser J.; Honisch E.; Kubisch C.; Wichmann H.E.; Kast K.; Deissler H.; Engel C.; Muller-Myhsok B.; Neveling K.; Kiechle M.; Mathew C.G.; Schindler D.; Schmutzler R.K.; Hanenberg H.;
Nat. Genet. 42:410-414(2010)
Cited for: VARIANTS ARG-3; THR-126; ASN-159; ALA-169; SER-264; VAL-264; ALA-287 AND GLN-366; VARIANTS BROVCA3 VAL-125 AND PHE-138;

Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients.
Thompson E.R.; Boyle S.E.; Johnson J.; Ryland G.L.; Sawyer S.; Choong D.Y.; Chenevix-Trench G.; Trainer A.H.; Lindeman G.J.; Mitchell G.; James P.A.; Campbell I.G.;
Hum. Mutat. 33:95-99(2012)
Cited for: VARIANTS LEU-52; PHE-103 DEL; VAL-114; THR-126; ALA-169; THR-175; CYS-249; VAL-262 AND SER-264; VARIANTS BROVCA3 GLU-162; PRO-178 AND ALA-287;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.